Diagnosis

Patients With Smoldering Multiple Myeloma Report Symptoms and Quality of Life Impacts

This qualitative study explored the health-related quality of life (HRQoL) and symptom burden in patients with smoldering multiple myeloma (SMM), a precursor to multiple myeloma (MM) traditionally considered...
CURATED BY: Jill N. Burke,
CNP, DipACLM

Infection Risk Management in Multiple Myeloma: IMWG Guidelines for Prevention and Prophylaxis

Patients with multiple myeloma (MM) face a high risk of infections, particularly in the early stages of diagnosis and during treatment....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Improving Diagnosis and Outcomes in Multiple Myeloma: Early Detection and Healthcare Disparities

Multiple myeloma (MM) is a hematologic malignancy that impacts plasma cells in the bone marrow, causing symptoms such as bone lesions, renal injury, anemia, and hypercalcemia....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Comprehensive Advances in Multiple Myeloma: From Diagnosis to Emerging Therapies

Multiple myeloma is a plasma cell cancer that often develops from precursor conditions like monoclonal gammopathy of undetermined significance or smoldering multiple myeloma (SMM)....
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Advances in MRD Testing for Multiple Myeloma: Impact on Prognosis and Treatment Decisions

This article reviews the role of minimal residual disease (MRD) testing in multiple myeloma (MM), highlighting its association with improved progression-free survival and overall survival. MRD-negative status correlates with better...
CURATED BY:
Jill N. Burke,
CNP, DipACLM

IsaPd Shows Promise in Dara-R Multiple Myeloma, but Modest PFS Highlights Need for New Therapies

Researchers of a multicenter real-world analysis assessed the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara-R). The study...
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Impact of Removing 24-Hour Urine Assessments from IMWG Criteria in Patients With MM Post-ASCT

Researchers of this study analyzed the impact of removing 24-hour urine (24HRU) assessments from International Myeloma Working Group (IMWG) response criteria for patients with multiple myeloma (MM) following autologous stem...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN
Share